Pieris to Present at BioCentury Future Leaders in the Biotech Industry Conference

  //health-fitness.news-articles.net/content/2011/ .. -leaders-in-the-biotech-industry-conference.html
  Published in Health and Fitness on Monday, April 11th 2011 at 2:40 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

Pieris to Present at BioCentury Future Leaders in the Biotech Industry Conference -- FREISING, Germany, April 11, 2011 /PRNewswire/ --

FREISING, Germany, April 11, 2011 /PRNewswire/ -- Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium Broadway Hotel & Conference Center in New York, New York. Mr. Yoder and Dr. Laurent Audoly, Chief Scientific Officer, will be available to respond to questions during a breakout session immediately following the presentation, and to participate in one-on-one meetings.

Event: BioCentury Future Leaders in the Biotech Industry Conference 2011

Date: Friday, April 15, 2011

Time: 9:30 am ET (Breakout Session: 10:00-10:30 am ET)

Place: The Millennium Broadway Hotel & Conference Center, New York, NY (Room 402/403)

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin(r) technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches. Pieris' pipeline ranges from its Phase I compound, PRS-050 (anti-VEGF, oncology), to multiple Anticalins in preclinical development. The company has three ongoing collaborations: a drug discovery partnership with Takeda San Francisco; a multi-year, multi-target agreement with Sanofi-Aventis and Sanofi Pasteur (EUROMEXT: SAN and NYSE: SNY); and a deal with Allergan, Inc. (NYSE: AGN), focusing on novel treatments for eye diseases. Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. For more information, please visit: [ http://www.pieris-ag.com ].

 For more information, please contact: Stephen Yoder, CEO Pieris AG +49(0)8161-1411-400 [ info@pieris-ag.com ]

SOURCE Pieris AG